

Day 2 Roadmap

Mark Levenson, Ph.D.
Director
Division of Biometrics 7
Center for Drug Evaluation and Research
US Food and Drug Administration

Overall Roadmap



 Day 1: Focused on improving the use of existing data sources used in ADF evaluation

 Day 2: Focused on use and development of new sources and capabilities for ADF evaluation

Objectives



• To determine whether the marketing of a product with abuse-deterrent properties results in meaningful reductions in abuse, misuse, and related adverse clinical outcomes, including addiction, overdose, and death in the postapproval setting (2015 Guidance).

 To determine whether products discourage riskier forms of abuse and misuse

Populations



- At least one study should include a high-risk population, such as a population of known drug abusers, but formal studies should not be limited to only high-risk populations (2015 Guidance)
 - Known drug abusers
 - Patients with new prescriptions
 - Patients on the verge of abuse

Requirements



- Identification of product-specific information, including brand and formulation
- Information on routes of abuse
- Ability to be rapidly modified, in response to changes in the prescription drug market
- Rigorous and valid outcome ascertainment
- Comparability over products
- Stability over time

Requirements (cont.)



- Well-defined populations, through probability sampling or otherwise
- Ability to measure in different populations (regions, at risk populations, demographic subgroups)
- Ability to handle drugs with small market share

 To accomplish all this, we may need multiple data sources and studies.

Data Sources: Examples



• Probability sample: NSDUH


• **Cohort**: FDA PMR 3033-2

• Combination: Hispanic Community Health Study

National Survey on Drug Use and Health



Multistage area probability design



National Survey on Drug Use and Health



- Multistage area probability design
- Youths aged 12 to 17 and young adults aged 18 to 25 are oversampled
- Prescription drug use focus on 12 month period
- Questions on misuse
- Electronic images of pills used for identification

FDA Post-Market Requirement 3033-2



 An observational study using patient health records, insurance claims, and death records

 Two companion studies to develop and validate algorithms using coded medical terminologies for opioid-related overdose, death, abuse, and misuse

Probability Sample Designs



- Subjects randomly selected from some welldefined population
- Longitudinal information may or may not be obtained
- Rigorous inference to population is possible

Eg. Incidence=

pop. est. of subjects w/exposure and w/event

pop. est. subjects w/exposure

Cohort Designs



- Subjects satisfying well-defined inclusion/exclusion criteria
- Subjects have longitudinal information on exposure, risk factors, and at risk for outcomes
- Incidences and relative risks based on aggregating subject level information

Eg. Incidence=

subjects in cohort with exposure and event

subjects in cohort with exposure




Cohort and Probability Sample Designs

	Cohort Study	Probability Sample
Provides a direct denominator	✓	\checkmark
Inferred population/representativeness	Cohort	Population
Allows valid estimates of incidence	✓	✓
Allows exploration of relationships (eg, exposure/outcome)	✓	✓
Challenges	Identifying appropriate cohort and obtaining information	Sampling or enriching for certain populations

Simulated Comparison of Population and Cohort Estimates



Average number of work days missed per year due to illness or injury



Hispanic Community Health Study



Objectives:

- Estimate prevalences of baseline risk factors
- Evaluate relationships between risk factors and health outcomes

Design:

- Probability sample embedded in multisite cohort study
- Subjects 16,000 Hispanic/Latinos 18-74 y
- Data collection: baseline and annual examinations

Hispanic Community Health Study: DA Subject Select





Chosen to be enriched in Hispanics and provide breadth

Census Tracks Non-Random

Chosen for proximity to clinics and breadth

Census Blocks Random

Stratified random sampling

Households Random

Stratified random sampling

Day 2 Sessions



- Session 5 National surveys: Opportunities for Evaluation of ADFs
- Session 6 Designs That Assess Exposure and Outcome in the Same Individuals Over Time
- Session 7 Leveraging other data: Linkages and Benchmarking
- Session 8 Next steps

Discussion and Feedback



- Utility, strengths, and limitations of the existing national surveys
- Approaches and feasibility to modifying existing national surveys
- Development of new surveys, including internet panel surveys and other designs
- Novel study designs, including longitudinal cohort studies, and leveraging/linking multiple data sources
- Smaller local or regional studies and other types of information